A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum- sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup ( GCIG)

被引：0
作者：
Pujade-Lauraine, E.
Mahner, S.
Kaern, J.
Gebski, V.
Heywood, M.
Vasey, P.
Reinthaller, A.
Vergote, I.
Pignata, S.
Ferrero, A.
机构：
[1] GINECO, Paris, France
[2] AGO OVAR, Hamburg, Germany
[3] NSGO, Oslo, Norway
[4] ANZGOG, Sydney, NSW, Australia
[5] NCIC, CTG, Vancouver, BC, Canada
[6] ANZGOG, Queensland, Australia
[7] AGO Austria, Vienna, Austria
[8] Eortc Data Ctr, Louvain, Belgium
[9] MITO, Naples, Italy
[10] MANGO, Turin, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
[31]   A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer [J].
D D Gibbs ;
L Pyle ;
M Allen ;
M Vaughan ;
A Webb ;
S R D Johnston ;
M E Gore .
British Journal of Cancer, 2002, 86 :1379-1384
[32]   A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer [J].
Gibbs, DD ;
Pyle, L ;
Allen, M ;
Vaughan, M ;
Webb, A ;
Johnston, SRD ;
Gore, ME .
BRITISH JOURNAL OF CANCER, 2002, 86 (09) :1379-1384
[33]   Phase III randomized trial of maintenance pegylated liposomal doxorubicin (PLD) / carboplatin versus without in patients with advanced ovarian cancer: An Asian Gynecologic Oncology Group study. [J].
Lai, Chyong-Huey ;
Vallikad, Elizabeth ;
Lin, Hao ;
Yang, Lan-Yan ;
Ou, Yu-Che ;
Chou, Hung-Hsueh ;
Lin, Cheng-Tao ;
Huang, Huei-Jean ;
Huang, Kung-Gen ;
Qiu, Jentai ;
Hung, Yao-Ching ;
Wu, Tzu-I .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[34]   Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial [J].
Pignata, Sandro ;
Scambia, Giovanni ;
Ferrandina, Gabriella ;
Savarese, Antonella ;
Sorio, Roberto ;
Breda, Enrico ;
Gebbia, Vittorio ;
Musso, Pietro ;
Frigerio, Luigi ;
Del Medico, Pietro ;
Lombardi, Alessandra Vernaglia ;
Febbraro, Antonio ;
Scollo, Paolo ;
Ferro, Antonella ;
Tamberi, Stefano ;
Brandes, Alba ;
Ravaioli, Alberto ;
Valerio, Maria Rosaria ;
Aitini, Enrico ;
Natale, Donato ;
Scaltriti, Laura ;
Greggi, Stefano ;
Pisano, Carmela ;
Lorusso, Domenica ;
Salutari, Vanda ;
Legge, Francesco ;
Di Maio, Massimo ;
Morabito, Alessandro ;
Gallo, Ciro ;
Perrone, Francesco .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27) :3628-3635
[35]   A randomized phase III study of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLD) in progressive/recurrent ovarian cancer (OC) [J].
Ferrandina, G. ;
Lorusso, D. ;
Pignata, S. ;
Breda, E. ;
Savarese, A. ;
Nardi, M. ;
Scaltriti, L. ;
Ludovisi, M. ;
Scambia, G. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[36]   Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer [J].
Gordon, AN ;
Granai, CO ;
Rose, PG ;
Hainsworth, J ;
Lopez, A ;
Weissman, C ;
Rosales, R ;
Sharpington, T .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3093-3100
[37]   Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive epithelial ovarian cancer (EOC) [J].
Kim, Kenneth H. ;
Jelovac, Danijela ;
Armstrong, Deborah Kay ;
Weil, Susan ;
Phillips, Martin ;
Schwartz, Benjamin M. ;
Estes, Jacob Michael ;
Alvarez, Ronald David .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[38]   Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in subjects with platinum-sensitive epithelial ovarian cancer (EOC). [J].
Jelovac, D. ;
Armstrong, D. K. ;
Weil, S. ;
Phillips, M. ;
Schwartz, B. M. ;
Estes, J. M. ;
Alvarez, R. D. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[39]   Paclitaxel/carboplatin (TC) versus paclitaxel/carboplatin followed by topotecan (TOP) in first line treatment of advanced ovarian cancer.: Mature results of a gynecologic cancer interGroup (GCIG) phase III trial of the AGO OVAR and GINECO [J].
Pujade-Lauraine, E. ;
Meden, H. ;
Hardy-Bessard, A. C. ;
Nitz, U. ;
Mousseau, M. ;
Blohmer, J. U. ;
Flesch, M. ;
Staehle, A. ;
Mefti, F. ;
Pfisterer, J. .
EJC SUPPLEMENTS, 2005, 3 (02) :263-263
[40]   CARBOPLATIN PLUS PACLITAXEL VERSUS CARBOPLATIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH OVARIAN CANCER: THE MITO-2 (MULTICENTRE ITALIAN TRIALS IN OVARIAN CANCER) RANDOMIZED PHASE III TRIAL [J].
Pignata, S. ;
Scambia, G. ;
Savarese, A. ;
Sorio, R. ;
Breda, E. ;
Ferrandina, G. ;
Murgia, V. ;
Tamberi, S. ;
Signoriello, S. ;
Di Maio, M. .
ANNALS OF ONCOLOGY, 2010, 21 :304-304
12345